|
Report Date : |
29.10.2013 |
IDENTIFICATION DETAILS
|
Name : |
2P2D SOLUTIONS
LTD. |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
09.01.2007 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Developers of devices providing practical solutions to problems facing
drug monitoring and control throughout clinical trials (real-time monitoring
and documentation of participants’ drug compliance and protocol adherence). |
|
|
|
|
No. of Employees : |
3 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
In Development Process |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
|
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Source
: CIA |
2P2D SOLUTIONS
LTD.
Telephone 972
3 561 94 53
Mobile 972
54 769 35 17; 52 654 55 58
Fax 972
3 561 94 53
Email: ofer.baram@2P2D.com
18/6 Bitzaron Street
Tel Aviv 6789449 Israel
A Private Limited Company, incorporated as per file No. 51-392120-5 on
the 09.01.2007.
Authorized share capital NIS 100,000.00, divided into -
10,000,000 ordinary
shares of NIS 0.01 each,
of which 122,608 shares amounting to NIS 1,226.08 were issued.
1. MOFET B'YEHUDA - INDUSTRIAL RESEARCH
& DEVELOPMENT IN JUDEA LTD., 40.8%, a technological incubator, part of
TRENDLINES FUND Group, headed by Steven Rhodes and Todd Dollinger,
2. Ofer Baram, 25.6%,
3. Mordechai (Moti) Peer,
25.6%,
4. Ran Frenkel, 8%.
1. Shem-Tov Bachar,
Chairman,
2. Mordechai (Moti) Peer,
Joint General Manager,
3. Ofer Baram, Joint
General Manager,
4. Steven Rhodes, of
TRENDLINES,
5. Yossi Ron, CEO of MOFET
B'YEHUDA.
Developers of devices providing practical solutions to problems facing
drug monitoring and control throughout clinical trials (real-time monitoring
and documentation of participants’ drug compliance and protocol adherence).
Subject is at final stages of development, sales are expected to
commence in 2014.
Operating from office premises at the private residence of Ofer Baram,
in 18/6 Bitzaron Street, Tel Aviv. Also using additional offices in 54
Haatzmaut Street, Yehud.
Having 3 employees.
Subject's General Manager informed us that US$ 1,000,000 was invested so
far in development.
Other financial data not forthcoming.
There are no charges registered on the company's assets.
No sales as of yet.
MOFET B'YEHUDA - INDUSTRIAL RESEARCH & DEVELOPMENT IN JUDEA LTD., a
technological incubator, established 1991, investing in start-up companies
various fields (agriculture, water, environment, medical device,
communications, information and more). In 2007 it was privatized and was
acquired by TRENDLINES FUND Group.
TRENDLINES FUND Group, established 1993, a venture investment group,
investing in early-stage medical and agricultural technology companies in
Israel, having a portfolio of over 60 invested companies.
Bank Leumi Le'Israel Ltd., Airport City Branch (No. 938), Lod.
Nothing unfavorable learned.
Subject officials refused to disclose financial data, besides investment
in R&D figure.
TRENDLINES FUND is a leading venture capital fund in the agritech and
medical device fields, currently in the process of raising NIS 300 million.
Israel is considered one of the leading countries in the world in terms
of investment in the Life Science and Biotechnology industry. In 2008 Israel
was ranked 4th in investments in Biotechnology/GDP, while being
among the leaders in the areas of investments and patents in Medical Device and Bio-Pharma fields.
According to the Israel Association of Electronics
& Software, hi-tech industries sales in 2012 summed up to US$ 25.6 billion,
just over 3% rise from 2011 (then sales were US$ 24.825 billion, up from US$
23.5 billion in 2010 and US$ 22.85 billion in 2009). 2012 sales divided into
export of US$ 21.5 billion (US$ 20.97 billion, US$19.9 billion & US$ 19.45
billion in 2011, 2010 & 2009, respectively) and US$ 4.1 billion of sales to
the local market (US$ 3.855 billion, US$ 3.6 billion & US$ 3.4 billion in
2011, 2010 & 2009, respectively).
The division of companies by production within the
branches in 2011 was: 23% Civilian Communications & Telecommunications, 22%
Software, 18% Industrial Equipment, 16% Defense Systems, 14% Components and 7%
Medical Systems.
According to the Israel Venture Capital (IVC) research firm, after in
2011 there was a pick in the volume of capital raise by Israeli start-ups, the
global economic crisis gave its signs in 2012 with a decrease in venture
capital raise. In 2012 575 Israeli start ups raised US$ 1.92 billion from local
and foreign investors, 10% down from 2011 (US$ 12.14 billion raised by 545
start-ups, in 2010: US$ 1.26 billion raised by 391 start-ups), mainly from
foreign VC funds. The share of investment by local VC funds fell by 19%, though
the gap was mainly filled with investments by micro funds and angles.
The Life Science fields absorbed most of the investments (26%– around
US$ 500 million, 28% up from 2011), followed by the Internet field (21%).
VC funds operating in Israel managed to recruit over US$ 0.5 billion,
after several draft years.
2012 is also characterized n a record year of 'exits', with close to US$
10 billion paid for Israeli companies (or founded by Israeli entrepreneurs).
In principle, subject is good for trade engagements. However being a
start-up, no sales as of yet and lacking financial data, it is difficult to
determine credit.
Note: Since February 2013 Israel Post has started using a new area code
method of 7 digits (the old method of 5 digits is no longer valid).
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.50 |
|
|
1 |
Rs.99.49 |
|
Euro |
1 |
Rs.84.88 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors
are apparent. Repayment of interest and principal sums in default or expected
to be in default upon maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.